Clinical Trial

Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

Study acronym: MELODY
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Maintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-12; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2026-01-15
Trial Details
NCT Number NCT06981637
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: National Taiwan University Hospital, Chang Gung Memorial Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taipei Veterans General Hospital, Taiwan, National Cheng-Kung University Hospital, Tri-Service General Hospital (TSGH), China Medical University Hospital
Conditions Advanced Soft Tissue Sarcoma
Enrollment 81 participants
Start Date 2025-12-31
Primary Completion 2028-07-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-02